Publications

Browse Publications:

By Category:

• Abstract Posters (8)
• Research Papers (133)
• Presentations (6)

By Physician:

• David Charytan, MD (9)
• Donald E. Cutlip, MD (74)
• Ralph D'Agostino, PhD (15)
• Elazer R. Edelman, MD, PhD (5)
• Maurizio Fava, MD (5)
• Lawrence Garcia, MD (0)
• Ernest V. Gervino, Sc.D., FACSM (1)
• Michael Gibson, MD (4)
• Kalon K.L. Ho, MD, MSc (21)
• Michael Jaff, MD (0)
• Mark Josephson, MD (9)
• Joseph Massaro, PhD (17)
• Laura Mauri, MD (35)
• Andrew Nierenberg, MD (0)
• Mark H. Pollack, MD (1)
• Jeffrey J. Popma, MD (46)
• Matthew R. Reynolds, M.D, M.Sc. (18)
• Alexei Shvilkin, MD, PhD (5)
• Peter Zimetbaum, MD (30)

Category: Research Papers

Claudication: exercise vs endoluminal revascularization (CLEVER) study update. J Vasc Surg. 2009 Oct;50(4):942-945.e2.

SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Am Heart J. 2009 Oct;158(4):520-526.e2.

Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc Interv. 2009 Oct;2(10):967-76.

Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv. 2009 Oct;2(10):977-85.

In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT...registry. JACC Cardiovasc Interv. 2009 Aug;2(8):767-75.

Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol. 2009 Aug;2(4):362-9.

Five-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: eNDEAVOR I, first-in-human study. Catheter Cardiovasc Interv. 2009 Jul 13.

Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting. JACC Cardiovasc Interv. 2009 Jun;2(6):498-503.

Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol. 2009 Apr 28;53(17):1488-97.

A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): initial U.S. experience. JACC Cardiovasc Interv. 2009 Feb;2(2):91-6.

In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT...registry. JACC Cardiovasc Interv. 2009 Jan;2(1):37-45.

Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents. Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System. Circulation. 2009 Jan 26.

Multivessel drug-eluting stenting and impact of diabetes mellitus-A report from the EVENT registry. Catheter Cardiovasc Interv. 2008 Dec 9.

A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial. JACC Cardiovasc Interv. 2008 Oct;1(5):524-32.

Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation. 2008 Oct 28;118(18):1817-27.

Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med. 2008 Sep 25;359(13):1330-42.

Location of acute coronary artery thromboses in patients with and without chronic kidney disease. Kidney Int. 2008 Sep 24.

3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial. JACC Cardiovasc Interv. 2008 Aug;1(4):439-48.

Quality of life in atrial fibrillation: measurement tools and impact of interventions. J Cardiovasc Electrophysiol. 2008 Jul;19(7):762-8.

A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: results of the AMEthyst randomized controlled trial. JACC Cardiovasc Interv. 2008 Jun;1(3):248-57.

The Claudication: Exercise Vs. Endoluminal Revascularization (CLEVER) study: rationale and methods. J Vasc Surg. 2008 Jun;47(6):1356-63.

Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. J Am Coll Cardiol. 2008 May 13;51(19):1844-53.

The Claudication: Exercise Vs. Endoluminal Revascularization (CLEVER) study: Rationale and methods. J Vasc Surg. 2008 Apr 24.

Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008 Apr 23;299(16):1903-13.

Studies of Drug-Eluting Stents: To Each His Own? Circulation 2008 Apr 22;117(16):2047-50.

Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med. 2008 Apr 10;358(15):1572-9.

Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials. Heart. 2008 Mar;94(3):322-8.

Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients. Circulation. 2008 Feb 12;117(6):790-7.

Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation.... J Am Coll Cardiol. 2008 Feb 5;51(5):546-51.

Quality of Life in Atrial Fibrillation: Measurement Tools and Impact of Interventions. J Cardiovasc Electrophysiol. 2008 Feb 4

Prevalence and Prognostic Significance of Pre-Procedure Cardiac Troponin Elevation among Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results from the EVENT Registry. Circulation 2008 (in press).

Coronary magnetic resonance vein imaging: imaging contrast, sequence, and timing. Magn Reson Med. 2007 Dec;58(6):1196-206.

Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007 Dec 27;357(26):2657-65.

Drug eluting stents for ST-elevation myocardial infarction: risk and benefit J Thromb Thrombolysis. 2007 Dec;24(3):293-9.

Gender-specific outcomes after sirolimus-eluting stent implantation. J Am Coll Cardiol. 2007 Nov 27;50(22):2111-6.

The conundrum of late and very late stent thrombosis following drug-eluting stent implantation. Curr Opin Cardiol. 2007 Nov;22(6):565-571.

Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study. Am J Cardiol. 2007 Oct 22;100(8B):56M-61M.

The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. J Am Coll Cardiol. 2007 Oct 9;50(15):1442-9.

Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol. 2007 Oct 2;50(14):1299-304.

Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). Am J Cardiol. 2007 Sep 1;100(5):818-23.

Risk of target lesion revascularization after coronary stenting in patients with and without chronic kidney disease. Nephrol Dial Transplant. 2007 Sep;22(9):2578-85.

Impact of Late Incomplete Stent Apposition After Sirolimus-Eluting Stent Implantation on 4-Year Clinical Events. Intravascular Ultrasound Analysis from the Multicenter, Randomized, RAVEL, E-SIRIUS and SIRIUS Trials.Heart. 2007 Aug 29; [Epub ahead of print]

Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation. 2007 Jun 5;115(22):2842-7.

Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007 May 9;297(18):2001-9.

Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 May 1;115(17):2344-51.

A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007 Mar 8;356(10):989-97.

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007 Mar 8;356(10):998-1008.

Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007 Mar 8;356(10):1020-9.

Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial. Minerva Cardioangiol. 2007 Feb

Devices for Distal Protection During Percutaneous Coronary Revascularization. Circulation 2006; 113;2651-2656

Drug-eluting stent era: will we improve 5-year outcomes? Coron Artery Dis. 2006 Dec;17(8):681-4.

Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006 Dec 19;48(12):2440-7.

Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation:.... Am Heart J. 2006 Dec;152(6):1097-103.

Relationship of chronic kidney disease to cardiovascular death and myocardial infarction following coronary stenting. J Nephrol. 2006 Nov-Dec;19(6):764-70.

Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials). Am J Cardiol. 2006 Sep 15;98(6):718-21.

The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. Am Heart J. 2006 Sep;152(3):558-64.

Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. J Am Coll Cardiol. 2006 Jul 18;48(2):253-61.

Clopidogrel treatment surrounding percutaneous coronary intervention: when should it be started and stopped? Curr Cardiol Rep. 2006 Jul;8(4):267-71.

Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J. 2006 Jul;152(1):59-66.

A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among...agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol. 2006 Jun 20;47(12):2364-73.

Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol. 2006 Jul 4;48(1):32-6.

Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol. 2006 Jun 20;47(12):2374-9.

Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. Am J Cardiol. 2006 May 15;97(10):1473-7.

Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. Eur Heart J. 2006 Apr;27(8):920-8.

Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol. 2006 Apr 4;47(7):1350-5.

Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA. 2006 Mar 15;295(11):1264-73.

Drug-Eluting Stenting for Unprotected Left Main Coronary Artery Disease. JACC February 21, 2006:878-81.

Cardiac Enzyme Elevation After Successful Percutaneous Coronary Intervention Is Not an Independent Predictor of Adverse Outcomes. Circulation 2005;112;916-923.

Coronary drug-eluting stent development: Issues in trial design. Am Heart J 2005;149:415-33.

A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol. 2005 Nov 15;46(10):1812-9.

Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era. Am Heart J. 2005 Nov;150(5):887-92.

Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation. 2005 Nov 1;112(18):2833-9.

Obesity and clinical restenosis after coronary stent placement. Am Heart J. 2005 Oct;150(4):821-6.

Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison.Circulation. 2005 Jun 28;111(25):3435-42.

Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol. 2005 May 15;95(10):1140-5.

Surrogates, Substudies, and Real Clinical End Points in Trials of Drug-Eluting Stents. JACC April 19, 2005:1206-12.

Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004 Oct 7;351(15):1493-501.

Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation. 2004 Sep 7;110(10):1226-30.

Pubmed_ResultsPanel.Pubmed_RVDocSum Circulation. 2004 Aug 3;110(5):508-14. Epub 2004 Jul 19.

Clinical and economic outcomes of percutaneous coronary interventions in the elderly: an analysis of medicare claims data. Circulation. 2004 Jul 20;110(3):259-64.

Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study. Health Policy. 2004 Nov;70(2):207-16.

Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction:.... J Am Coll Cardiol. 2004 Sep 15;44(6):1215-23.

Effects of stent length and lesion length on coronary restenosis. Am J Cardiol. 2004 Jun 1;93(11):1340-6, A5.

Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) trial. Circulation. 2004 Jun 8;109(22):2727-31.

Drug-eluting Stent Task Force: Final report and recommendations of the Working Committees on Cost-Effectiveness/Economics, Access to Care, and Mediolegal Issues. Catheter Cardiovasc Interv. 2004 May;62(1):1-17.

Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004 Feb 10;109(5):634-40.

Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries. J Am Coll Cardiol. 2003 Dec 3;42(11):2007-13.

Impact of a practice guideline for patients with atrial fibrillation on medical resource utilization and costs. Am J Cardiol. 2003;92(6):677-81.

Incidence and predictors of late total occlusion following coronary stenting. Catheter Cardiovasc Interv. 2003 Nov;60(3):344-51.

Vascular brachytherapy using a beta emitter source in diabetic patients with in-stent restenosis: angiographic and clinical outcomes. Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):536-42.

Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003 Oct 2;349(14):1315-23.

Safety and efficacy of a novel device for treatment of thrombotic and atherosclerotic lesions in native coronary arteries and saphenous vein grafts: results from the multicenter X-Sizer for treatment of thrombus and atherosclerosis in coronary application

Reproducibility of coronary lumen, plaque, and vessel wall reconstruction and of endothelial shear stress measurements in vivo in humans. Catheter Cardiovasc Interv. 2003 Sep;60(1):67-78.

Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation. 2003 Aug 5;108(5):548-53.

Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: a randomized study (ATLAS). Circulation. 2003 May 13;107(18):2331-6.

Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol. 2003 May 1;91(9):1055-9.

Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART). Am Heart J. 2003 May;145(5):84

Use of Electrocardiogram in Acute Myocardial Infarction. N Engl J Med 2003 March 6;348:933-40.

Application of models for multivariate mixed outcomes to medical device trials: coronary artery stenting. Stat Med. 2003 Jan 30;22(2):313-36.

Treatment of coronary stent thrombosis with rheolytic thrombectomy: results from a multicenter experience. Catheter Cardiovasc Interv. 2003 Jan;58(1):11-7.

Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002 Dec 18;40(12):2082-9.

Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol. 2002 Dec 4;40(11):1928-34.

A decade of improvement in the clinical outcomes of percutaneous coronary intervention for multivessel coronary artery disease. Circulation. 2002 Sep 24;106(13):1592-4.

Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial. Am J Cardiol. 2002 Nov 15;90(10):1079-83.

Randomized trial of 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis. Circulation. 2002 Aug 27;106(9):1090-6.

Long-term outcome of patients treated with repeat percutaneous coronary intervention after failure of gamma-brachytherapy for the treatment of in-stent restenosis. Circulation. 2002 Oct 29;106(18):2340-5.

Effect of catheter-based iridium-192 gamma brachytherapy on the added risk of restenosis from diabetes mellitus after intervention for in-stent restenosis (subanalysis of the GAMMA I Randomized Trial). Am J Cardiol. 2002 Aug 1;90(3):243-7.

Cost-effectiveness of gamma radiation for treatment of in-stent restenosis: results from the Gamma-1 trial. Circulation. 2002 Aug 6;106(6):691-7.

Current clinical characteristics and economic impact of subacute stent thrombosis. J Invasive Cardiol. 2002 Jul;14(7):364-8.

Distal filter protection during saphenous vein graft stenting: technical and clinical correlates of efficacy. J Am Coll Cardiol. 2002 Nov 20;40(10):1882-8. Review.

Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts.Circulation. 2002 Mar 19;105(11):1285-90.

Sample size calculation for a historically controlled clinical trial with adjustment for covariates. J Biopharm Stat. 2002 May;12(2):227-47.

Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation. 2002 Apr 30;105(17):2012-8.

Comparison of PRE-dilatation vs direct stenting in coronary treatment using the Medtronic AVE S670 Coronary Stent System (the PREDICT trial).Am J Cardiol. 2001 Dec 15;88(12):1364-9.

Economic assessment of rheolytic thrombectomy versus intracoronary urokinase for treatment of extensive intracoronary thrombus: Results from a randomized clinical trial. Am Heart J. 2001 Oct;142(4):648-56.

Clinical and angiographic outcomes after use of 90Strontium/90Yttrium beta radiation for the treatment of in-stent restenosis: results from the Stents and Radiation Therapy 40 (START 40) registry. Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1075-82.

A trial comparing rheolytic thrombectomy with intracoronary urokinase for coronary and vein graft thrombus (the Vein Graft AngioJet Study [VeGAS 2]). Am J Cardiol. 2002 Feb 1;89(3):326-30.

Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker's paradox?Circulation. 2001 Aug 14;104(7):773-8.

Results of the study to determine rotablator and transluminal angioplasty strategy (STRATAS). Am J Cardiol. 2001 Mar 15;87(6):699-705.

Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001 Apr 17;103(15):1967-71.

Preintervention arterial remodeling affects clinical outcome following stenting: an intravascular ultrasound study. J Am Coll Cardiol. 2001 Mar 15;37(4):1031-5.

Rheolytic thrombectomy during percutaneous revascularization for acute myocardial infarction: experience with the AngioJet catheter. Am Heart J. 2001 Mar;141(3):353-9.

Coronary artery stenting in the aged. J Am Coll Cardiol. 2001 Mar 1;37(3):856-62.

Immediate and late clinical outcomes of carotid artery stenting in patients with symptomatic and asymptomatic carotid artery stenosis: a 5-year prospective analysis. Circulation. 2001 Jan 30;103(4):532-7.

Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 2001 Jan 25;344(4):250-6.

Final results of a randomized trial comparing the NIR stent to the Palmaz-Schatz stent for narrowings in native coronary arteries. Am J Cardiol. 2001 Jan 15;87(2):152-6.

Final results of a randomized trial comparing the MULTI-LINK stent with the Palmaz-Schatz stent for narrowings in native coronary arteries. Am J Cardiol. 2001 Jan 15;87(2):157-62.

Effect of intracoronary gamma-radiation therapy on in-stent restenosis: An intravascular ultrasound analysis from the gamma-1 study. Circulation. 2000 Dec 12;102(24):2915-8.

The PARAGON stent study: a randomized trial of a new martensitic nitinol stent versus the Palmaz-Schatz stent for treatment of complex native coronary arterial lesions. Am J Cardiol. 2000 Nov 15;86(10):1073-9.

Impact of smoking on health-related quality of life after percutaneous coronary revascularization. Circulation. 2000 Sep 19;102(12):1369-74.

Short- and intermediate-term clinical outcomes from direct myocardial laser revascularization guided by biosense left ventricular electromechanical mapping. Circulation. 2000 Sep 5;102(10):1120-5.

Randomized comparison of GR-II stent and Palmaz-Schatz stent for elective treatment of coronary stenoses. Circulation. 2000 Sep 19;102(12):1364-8.

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998 Dec 3;339(23):1665-71.

Meet The HCRI Team

Donald Cutlip, MD

Executive Director of Clinical Investigations

Dr. Donald Cutlip is a leader in the field of interventional cardiology. Dr. Cutlip is one of the founding members of Cardiac Data Analysis…

Submit an RFP

Quick Links

• Contact HCRI
• Careers at HCRI
• Information for Patients

930-W Commonwealth Avenue
Boston MA 02215
t: 617.632.1515    f: 617.632.1580

©2009 Harvard Clinical Research Institute